替尼泊苷和洛莫司汀加用于联合化疗中预防肺癌脑转移  

TENIPOSIDE AND LOMUSTINE PLUS COMBINATION CHEMOTHERAPY IN THE PREVENTION OF BRAIN METASTASIS IN LUNG CANCER PATIENTS

作　　者：宁廷禄 

机构地区：[1]青岛市肿瘤医院

出　　处：《中国癌症杂志》1999年第2期112-114,共3页China Oncology

摘　　要：目的研究化疗药物对肺癌脑转移的预防作用。方法治疗组３６例系经病理确诊尚无脑转移的肺癌患者，采用含有替尼泊苷（威猛）和洛莫司汀（环己亚硝脲，ＣＣＮＵ）的联合化疗方案，每４～６周为１周期，３个周期为１个疗程。观察指标包括临床症状和体征，头颅ＣＴ或ＭＲＩ检查。随访时间４～３６月以上，对照组３６例，所用的联合化疗方案不含威猛和ＣＣＮＵ，其用药周期、疗程、观察指标及随访期限均与治疗组相同。结果治疗组与对照组脑转移的发生率分别为２８％和２５％（Ｐ＜００５）。结论提示威猛和ＣＣＮＵ的联合化疗方案对肺癌脑转移有一定的预防作用。PURPOSE To study the action of teniposide(vumon) plus lomustine(CCNU) in the prevention of brain metastasis in lung cancer patients. METHODS To ascertain if brain metastasiss is preventable,36 lung cancer patients without brain metastasis were treated by using tradional combination chemotherapy protocal with vumon and CCNU for 3 cycles at 4 or 6 week intervals. As a control,an equal number of lung cancer patients free of brain metastasis were treated with chemotherapy protocol which did not include vumon and CCNU.The patients were monitored by clinical symptoms,signs and CT or MRI scan and were followed up 4～12 months. RESULTS None of 36(2 8%) the vumon plus CCNU treated patients developed brain metastasis while brain metastasis occured in 9 of 36 (25%) control patients.The difference was statistically significant( P <0 05) CONCLUSIONS It is suggested that the combination chemotherapy plus vumon and CCNU is effective in prevention for brain metastasis in lung cancer patients.

关 键 词：肺癌 替尼泊苷 洛莫司汀 预防 脑转移瘤 

分 类 号：R734.205[医药卫生—肿瘤] R739.410.1[医药卫生—临床医学]